This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

1 Aug 2012

Suzhou Connect Enters Licensing Agreement with Arena

Suzhou Connect hopes to advance novel small molecule compounds for the treatment of allergic rhinitis and atopic dermatitis.

Suzhou Connect Biopharmaceuticals has entered into an exclusive worldwide licensing agreement with Arena Pharmaceuticals, through its wholly owned subsidiary Connect Biopharm LLC in the US.


The agreement relates to two series of novel small molecule compounds which have anti-inflammatory properties and could have the potential to treat allergic rhinitis and atopic dermatitis.

Related News